We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Two cases of 22q11.2 deletion syndrome with decreased serum calcium during recovery following thyrotoxicosis.
- Authors
Hiroshima, Shota; Taniguchi, Chihiro; Inoue, Mika; Sone, Hirohito; Nagasaki, Keisuke
- Abstract
In six cases of Graves' disease, hypocalcemia developed approximately 1-5 months after antithyroid drug initiation, and in patient 2, serum Ca levels began to decline even when FT4 levels were above the normal range. The most common chromosomal microdeletion syndrome, 22q11.2 deletion syndrome (22qDS), mainly manifests as hypoparathyroidism, which varies from overt to subclinical presentation, and is often asymptomatic.1 Parathyroid hormone (PTH) reserve, the response of PTH to the sodium bicarbonate infusion test, is reduced in many patients with 22qDS having normocalcemia.2 22qDS is associated with high-autoimmune thyroid disease incidence.3 Hypercalcemia due to thyrotoxicosis is rarely reported, which means that thyroid hormones affect calcium (Ca) metabolism.4 Although 22qDS with hypocalcemia following thyrotoxicosis is infrequently reported (Table S1),5 hypocalcemia timing and severity remain unclear.
- Publication
Congenital Anomalies, 2022, Vol 62, Issue 6, p254
- ISSN
0914-3505
- Publication type
Academic Journal
- DOI
10.1111/cga.12486